Keratoacanthomas associated with imatinib mesylate

Acta Oncologica

Volumn 50, Issue 4, 2011, Pages 593-595

  Balagula, Yevgeniy ^a   Busam, Klaus J ^a   Carvajal, Richard D ^a   Wolchok, Jedd D ^a   Myskowski, Patricia L ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMATINIB; TEMOZOLOMIDE;

AGED; CANCER SURGERY; CASE REPORT; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG INDUCED DISEASE; DRUG WITHDRAWAL; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; KERATOACANTHOMA; LETTER; MALE; MELANOMA; PRIORITY JOURNAL; RECURRENT CANCER;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; KERATOACANTHOMA; MALE; MELANOMA; PIPERAZINES; PYRIMIDINES; SKIN NEOPLASMS; TREATMENT OUTCOME;

EID: 79955614052     PISSN: 0284186X     EISSN: 1651226X     Source Type: Journal    
DOI: 10.3109/0284186X.2010.537690     Document Type: Letter

References (15)

1. Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, et al. Efficacy and safety of a specific inhibitor of the BCR ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001;344:1031-7. (Pubitemid 32267972)
2. Baskaynak G, Kreuzer KA, Schwarz M, Zuber J, Audring H, Riess H, et al. Squamous cutaneous epithelial cell carcinoma in two CML patients with progressive disease under imatinib treatment. Eur J Haematol 2003;70:231-4. (Pubitemid 36511317)
3. Scheinfeld N. Imatinib mesylate and dermatology part 2: A review of the cutaneous side effects of imatinib mesylate. J Drugs Dermatol 2006;5:228-31.
4. Breccia M, Carmosino I, Russo E, Morano SG, Latagliata R, Alimena G. Early and tardive skin adverse events in chronic myeloid leukaemia patients treated with imatinib. Eur J Haematol 2005;74:121-3. (Pubitemid 40175315)
5. Dubauskas Z, Kunishige J, Prieto VG, Jonasch E, Hwu P, Tannir NM. Cutaneous squamous cell carcinoma and inflammation of actinic keratoses associated with sorafenib. Clin Genitourin Cancer 2009;7:20-3.
6. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007;356:125-34. (Pubitemid 46089673)
7. Lacouture ME, McArthur GA, Chapman PB, Ribas A, Flaherty KT, Lee RJ, et al. PLX4032 (RG7204), a selective mutant RAF inhibitor: Clinical and histologic characteristics of therapy-associated cutaneous neoplasms in a phase I trial. J Clin Oncol 2010;28:7s(Suppl abstr 8592).
8. Bulj TK, Krunic AL, Cetner AS, Villano JL. Refractory aggressive keratoacanthoma centrifugum marginatum of the scalp controlled with the epidermal growth factor receptor inhibitor erlotinib. Br J Dermatol 2010.
9. Poulikakos PI, Zhang C, Bollag G, Shokat KM, Rosen N. RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature 2010;464(7287): 427-30.
10. Johnson FM, Saigal B, Donato NJ. Induction of heparinbinding EGF-like growth factor and activation of EGF receptor in imatinib mesylate-treated squamous carcinoma cells. J Cell Physiol 2005;205:218-27. (Pubitemid 41428904)
11. Reid DC, Guitart J, Agulnik M, Lacouture ME. Treatment of multiple keratoacanthomas with erlotinib. Int J Clin Oncol 2010;15:413-5.
12. Oertel S, Krempien R, Lindel K, Zabel A, Milker-Zabel S, Bischof M, et al. Human glioblastoma and carcinoma xenograft tumors treated by combined radiation and imatinib (Gleevec). Strahlenther Onkol 2006;182:400-7. (Pubitemid 44025008)
13. Wang-Rodriguez J, Lopez JP, Altuna X, Chu TS, Weisman RA, Ongkeko WM. STI-571 (Gleevec) potentiates the effect of cisplatin in inhibiting the proliferation of head and neck squamous cell carcinoma in vitro. Laryngoscope 2006;116: 1409-16. (Pubitemid 44181456)
14. Chu HR, Ongkeko WM, Diaz A, Altuna X, Aguilera J, Weisman RA, et al. Growth inhibition of head and neck squamous cell carcinoma by imatinib mesylate (Gleevec). Cancer Ther 2005;3:515-24.
15. Kawakami Y, Nakamura K, Nishibu A, Yanagihori H, Kimura H, Yamamoto T. Regression of cutaneous squamous cell carcinoma in a patient with chronic myeloid leukaemia on imatinib mesylate treatment. Acta Derm Venereol 2008;88: 185-6. (Pubitemid 351507203)